ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2008
Current and future standards in treatment of myasthenia gravis.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Thymectomy via open surgery or robotic video assisted thoracic surgery: Can a recommendation already be made?Medicine · 2017Pooled it
- Bridging the Heterogeneity of Myasthenia Gravis Scores as a Foundational Step Towards the Construction of a Digital Twin.Biomedicines · 2025Article
- Bridging the Heterogeneity of Myasthenia Gravis Severity Scores for Digital Twin Development.medRxiv : the preprint server for health sciences · 2025Article
- Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis.Frontiers in immunology · 2025Article
- Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod.Frontiers in neurology · 2024Article
- Stability monitoring of patients with myasthenia gravis using a mobile-based application.Current journal of neurology · 2023Article
- Effects of intravascular photobiomodulation on motor deficits and brain perfusion images in intractable myasthenia gravis: A case report.World journal of clinical cases · 2022Article
- Pathophysiological basis in the management of myasthenia gravis: a mini review.Inflammopharmacology · 2022Review
- Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country.Journal of central nervous system disease · 2021Article
- Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.International journal of molecular sciences · 2020Review
- Review
- Comparative Outcomes of Respiratory Failure Associated with Common Neuromuscular Emergencies: Myasthenia Gravis versus Guillain-Barré Syndrome.Medicina (Kaunas, Lithuania) · 2019Article
- Pediatric thymectomy: a study of national trends in demographics, short-term outcomes, and cost.Pediatric surgery international · 2019Article
- Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.Muscle & nerve · 2018Article
- Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China.Therapeutic advances in neurological disorders · 2017Article
- Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study.BMC neurology · 2016Article
- Pulmonary edema in myasthenic crisis.Case reports in critical care · 2013Article
- Myasthenia gravis: a review.Autoimmune diseases · 2012Article
- Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.Therapeutic advances in neurological disorders · 2011Article
- Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.Therapeutic advances in neurological disorders · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is a prototypic antibody-mediated neurological autoimmune disorder. Herein we characterize modern treatment algorithms that are adapted to disease severity, and introduce the current principles of escalating strategies for MG treatment. In non-thymoma patients younger than about 50 years of age and with generalized weakness, a complete early (but not urgent) thymectomy is considered as state-of-the-art on the basis of circumstantial evidence and expert opinion. In up to 10% of patients, MG is associated with a thymoma (i.e., is of paraneoplastic origin). The best surgical type of procedure is still under debate. Myasthenic crisis is best treated by plasmapheresis, mostly combined with immunoabsorption techniques. Intravenous immunoglobulins are a reasonable alternative, but a shortage in supplies and high prices limit their use. In generalized MG, a wide array of immunosuppressive treatments has been established, although not formally tested in double-blind, prospective trials. With regard to immunosuppression, azathioprine is still the standard baseline treatment, often combined with initial corticosteroids. In rare patients with an inborn hepatic enzyme deficiency of thiomethylation, azathioprine may be substituted by mycophenolate mofetil. Severe cases may benefit from combined immunosuppression with corticosteroids, cyclosporine A, and even with moderate doses of methotrexate or cyclophosphamide. Tacrolimus is under investigation. In refractory cases, immunoablation via high-dose cyclophosphamide followed by trophic factors such as granulocyte colony-stimulating factor has also been suggested. In the future we may face an increased use of novel, B-cell, or T-cell-directed monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.